Huang Y, Fan H, Li N, Du J. Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis. Cancer Med. 2019;8:2664--2674. 10.1002/cam4.2104 30950194

**Funding information**

This manuscript was funded by Beijing Outstanding Talent Training Project (2016000020124G097).

1. INTRODUCTION {#cam42104-sec-0005}
===============

Programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1) monoclonal antibodies have shown significant clinical activity and marked efficacy in the treatment of advanced cancers.[1](#cam42104-bib-0001){ref-type="ref"}, [2](#cam42104-bib-0002){ref-type="ref"}, [3](#cam42104-bib-0003){ref-type="ref"}, [4](#cam42104-bib-0004){ref-type="ref"}, [5](#cam42104-bib-0005){ref-type="ref"} Many PD‐1 and PD‐L1 monoclonal antibodies have already been approved by Food and Drug Administration (FDA), consider for example, avelumab, atezolizumab, durvalumab, nivolumab, and pembrolizumab.[3](#cam42104-bib-0003){ref-type="ref"}, [4](#cam42104-bib-0004){ref-type="ref"}, [5](#cam42104-bib-0005){ref-type="ref"}, [6](#cam42104-bib-0006){ref-type="ref"}, [7](#cam42104-bib-0007){ref-type="ref"} These regulatory approvals have resulted in a widespread prescribing of PD1/PD‐L1 inhibitors for patients with advanced cancer.[8](#cam42104-bib-0008){ref-type="ref"} However, PD1/PD‐L1 inhibitors could disrupt normal immune tolerance mechanisms and be associated with immune‐related adverse events.[9](#cam42104-bib-0009){ref-type="ref"} Many organ systems and normal tissue would be affected.[9](#cam42104-bib-0009){ref-type="ref"}, [10](#cam42104-bib-0010){ref-type="ref"} Immune‐related pneumonitis is one of clinical relevant and potentially life‐threatening adverse events.[10](#cam42104-bib-0010){ref-type="ref"}, [11](#cam42104-bib-0011){ref-type="ref"}

Although previous data from randomized controlled trials (RCTs) have already shown that PD1/PD‐L1 inhibitor‐related therapeutic regimens are likely to increase the risk of immune‐related pneumonitis,[1](#cam42104-bib-0001){ref-type="ref"}, [2](#cam42104-bib-0002){ref-type="ref"}, [3](#cam42104-bib-0003){ref-type="ref"}, [7](#cam42104-bib-0007){ref-type="ref"}, [12](#cam42104-bib-0012){ref-type="ref"} results from these RCTs are not consistent. Traditional systematic reviews and meta‐analyses were conducted to estimate the safety profile of PD1/PD‐L1 inhibitor.[13](#cam42104-bib-0013){ref-type="ref"}, [14](#cam42104-bib-0014){ref-type="ref"}, [15](#cam42104-bib-0015){ref-type="ref"}, [16](#cam42104-bib-0016){ref-type="ref"} However, due to lacking head‐to‐head direct evidence, comparative pneumonitis risk among different PD1/PD‐L1 inhibitor‐related therapeutic regimens have never been systematically studied.

Structured evidence on pneumonitis risk of PD1/PD‐L1 inhibitor‐related therapeutic regimens would be necessary for physicians in making clinical decisions. In this study, we carried out a systematic review and network meta‐analysis (NMA) to compare the immune‐related pneumonitis risk among different types of PD1/PD‐L1 inhibitor‐related therapeutic regimens simultaneously for cancer patients.

2. MATERIALS AND METHODS {#cam42104-sec-0006}
========================

2.1. Study design {#cam42104-sec-0007}
-----------------

We conducted a systematic review with both pairwise meta‐analysis and Bayesian NMA. The study was carried out according to the Cochrane handbook for systematic reviews of interventions.[17](#cam42104-bib-0017){ref-type="ref"} We reported the study according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines.[18](#cam42104-bib-0018){ref-type="ref"}, [19](#cam42104-bib-0019){ref-type="ref"} The study was registered in PROSPERO international prospective register of systematic reviews (CRD42018099163).

2.2. Search strategy and selection criteria {#cam42104-sec-0008}
-------------------------------------------

We systematically searched PubMed, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov to identify potentially eligible studies. The terms used for the search strategy included "neoplasm", "cancer", "atezolizumab", "avelumab", "durvalumab", "nivolumab", "pembrolizumab". There was no restriction on language or year of publication. We manually checked reference lists of related review articles to identify additional studies. The final date for the database running searches was June 19th, 2018.

Eligible studies had to be RCTs and should include either anti‐PD‐1 or anti‐PD‐L1 monoclonal antibody (ie atezolizumab, avelumab, durvalumab, nivolumab, pembrolizumab), alone or in combination with other types of treatment, in the intervention or control group. We evaluated the rates of immune‐related pneumonitis reported. We excluded studies only in abstract form and studies of quality of life or cost effectiveness analyses.

2.3. Study selection and data extraction {#cam42104-sec-0009}
----------------------------------------

Two independent investigators (HY and FH) selected the potentially eligible studies and extracted the data from all the eligible studies. The titles, abstracts, and full‐text records were evaluated sequentially. The following information was extracted: title, trial name, year, funding sources, line of treatment, blinding, age, sex, tumor type, length of follow up, types and dosage of drugs, number of patients in the treatment and control arms, number of patients with pneumonitis of all‐grade (grade 1‐5) and high‐grade (grade 3‐5) in the treatment and control arms. Both published and unpublished data were extracted. The unpublished data were extracted from ClinicalTrials.gov.

2.4. Quality assessment {#cam42104-sec-0010}
-----------------------

Two authors (HY and FH) independently assessed the risk of bias of included studies based on the Cochrane Collaboration\'s tool.[17](#cam42104-bib-0017){ref-type="ref"} Disagreement was resolved by discussion with a third author (LN). Six domains were evaluated: sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other sources of bias.

We used the Grading of Recommendations Assessment, Development and Evaluation system (GRADE) approach to rate the quality of evidence.[20](#cam42104-bib-0020){ref-type="ref"} There were 4 levels of quality of evidence: high, moderate, low, and very low. The quality of evidence for each outcome was based on the fundamental study design and additional methodological factors.[20](#cam42104-bib-0020){ref-type="ref"}

2.5. Outcome measures {#cam42104-sec-0011}
---------------------

The primary outcome of interest was all‐grade (grade 1‐5) pneumonitis. Secondary outcome was high‐grade (grade 3‐5) pneumonitis based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.

2.6. Statistical analysis {#cam42104-sec-0012}
-------------------------

DerSimonian‐Laird random effects model was used to perform traditional pairwise meta‐analyses. Summary effect size was presented as odds ratio (OR) for binary outcomes along with corresponding 95% confidence intervals (CIs). A 2‐sided *P* value of less than 0.05 or 95% CIs excluding one was regarded as statistically significant. Heterogeneity among studies was assessed using Cochrane *Q* statistic and quantified with *I* ^*2*^ statistic. Values over 50% indicated substantial heterogeneity.[17](#cam42104-bib-0017){ref-type="ref"} Publication bias was examined using funnel plots.[21](#cam42104-bib-0021){ref-type="ref"}

Bayesian NMA allowing for indirect comparisons was performed to evaluate the risk of pneumonitis using a Markov Chain Monte Carlo (MCMC) simulation technique. We estimated the posterior distribution of all parameters using vague priors. We updated the MCMC model with 100000 simulated draws after a burn‐ins of 10000 iterations and used a thinning interval of 10 for each chain. We tested the adequacy of burn‐in and convergence using the Brooks‐Gelman‐Rubin statistic.[22](#cam42104-bib-0022){ref-type="ref"} Relative effects of treatments were reported as OR for binary outcomes along with corresponding 95% credible intervals (CrIs). All analyses were performed under the random‐effects model since they generally showed more conservative estimated effects and better goodness of fit. We calculated the posterior mean of the residual deviance to determine goodness of fit of the models. Ideally, each data point should contribute about one to the posterior mean of the residual deviance. Therefore, it can be compared with the number of data points for model fit checking. We used the loop‐specific approach to evaluate the presence of inconsistency.[23](#cam42104-bib-0023){ref-type="ref"} We calculated the values of 2 odds ratios (RoR) from direct and indirect evidence in the loop with 95% CI to assess the presence of inconsistency in each loop. Inconsistency was defined as disagreement between direct and indirect evidence with a 95% CI excluding zero.

Meta‐regression analyses were performed by adding prespecified covariates (ie median age, percentage of male, line of treatment, study phase, whether double‐blind was used) to the network meta‐analysis models. Sensitivity analyses were performed to evaluate the robustness of results based on the events reported in published articles only. The data analyses were conducted using STATA version 14.0 and WinBUGs version 1.4.3.

3. RESULTS {#cam42104-sec-0013}
==========

3.1. Eligible studies and patient characteristics {#cam42104-sec-0014}
-------------------------------------------------

Initial search identified 5566 records. 4023 potentially eligible articles were retrieved for detailed assessment. Thirty articles reporting 25 studies were included for meta‐analysis (Figure [1](#cam42104-fig-0001){ref-type="fig"}, [Table S1](#cam42104-sup-0002){ref-type="supplementary-material"}). The 25 studies covered 12 types of treatment and involved a total of 16 005 cancer patients (Figure [2](#cam42104-fig-0002){ref-type="fig"}). The baseline characteristics of the included studies are listed in Tables [1](#cam42104-tbl-0001){ref-type="table"} and [2](#cam42104-tbl-0002){ref-type="table"} and [Table S2](#cam42104-sup-0002){ref-type="supplementary-material"}. The risk of bias summary for included studies is listed in [Table S3](#cam42104-sup-0002){ref-type="supplementary-material"}.

![Literature search and selection](CAM4-8-2664-g001){#cam42104-fig-0001}

![Network of eligible comparisons for the Bayesian network meta‐analysis. The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of comparisons (beside the line) comparing the connected treatment (nodes). A total of 25 randomized controlled trials included 30 comparisons were analyzed](CAM4-8-2664-g002){#cam42104-fig-0002}

###### 

Characteristics of eligible studies

  Trial name                  Year         Funding sources                                    Line of treatment           Study phase   Blinding       Median age   Age range   Sex (Male)   Tumor type                                      Length of follow up (month)   Treatment                                                                                                                                                                      
  --------------------------- ------------ -------------------------------------------------- --------------------------- ------------- -------------- ------------ ----------- ------------ ----------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------- -----------------------------------------------------------------------
  CheckMate 017               2015         Bristol‐Myers Squibb                               Second‐line                 Phase 3       Open‐label     63           39‐85       208          Non--small‐cell lung cancer                     Minimum 11                    Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Chemotherapy control
  CheckMate 025               2015         Bristol‐Myers Squibb                               Not clear                   Phase 3       Open‐label     62           18‐88       619          Renal‐cell carcinoma                            Minimum 14                    Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Everolimus 10 mg orally daily
  CheckMate 026               2017         Bristol‐Myers Squibb                               First‐line                  Phase 3       Open‐label     64           29‐89       332          Non--small‐cell lung cancer                     NA                            Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Chemotherapy control
  CheckMate 037               2018;2015    Bristol‐Myers Squibb                               Second‐line                 Phase 3       Open‐label     60           23‐85       261          Melanoma                                        Median 8.4                    Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Chemotherapy control
  CheckMate 057               2015         Bristol‐Myers Squibb                               Second‐line                 Phase 3       Open‐label     62           21‐85       319          Non--small‐cell lung cancer                     Minimum 13.2                  Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Chemotherapy control
  CheckMate 066               2015         Bristol‐Myers Squibb                               First‐line                  Phase 3       Double‐blind   65           18‐87       246          Melanoma                                        Median 8.9 and 6.8            Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Chemotherapy control
  CheckMate 067               2015;2017    Bristol‐Myers Squibb                               First‐line                  Phase 3       Double‐blind   60           18‐90       610          Melanoma                                        Median 12                     Nivolumab 3 mg/kg every 2 weeks                                                                        Nivolumab 1 mg/kg every 3 weeks plus ipilimumab 3 mg/kg every 3 weeks   Ipilimumab 3 mg/kg every 3 weeks
  CheckMate 069               2015         Bristol‐Myers Squibb                               First‐line                  Phase 2       Double‐blind   65           27‐87       95           Melanoma                                        Minimum 11                    Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks                                                NA                                                                      Ipilimumab 3 mg/kg every 3 weeks
  CheckMate 141               2016, 2018   Bristol‐Myers Squibb                               Second‐line or more         Phase 3       Open‐label     60           28‐83       300          Head and neck carcinoma                         Median 5.1                    Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Standard therapy control
  CheckMate 214               2018         Bristol‐Myers Squibb                               First‐line                  Phase 3       Open‐label     62           21‐85       808          Renal‐cell carcinoma                            Median 25.2                   Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks, followed by nivolumab 3 mg/kg every 2 weeks   NA                                                                      Sunitinib 50 mg once daily for 4 weeks
  CheckMate 227               2018         Bristol‐Myers Squibb                               First‐line                  Phase 3       Open‐label     64           29‐87       NA           Non--small‐cell lung cancer                     Minimum 11.2                  Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks                                  Nivolumab 240 mg every 2 weeks                                          Chemotherapy control
  CheckMate 238               2017         Bristol‐Myers Squibb and Ono Pharmaceutical        Not clear                   Phase 3       Double‐blind   55           18‐86       527          Melanoma                                        Minimum 18                    Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks
  KEYNOTE‐002                 2015, 2017   Merck Sharp & Dohme, a subsidiary of Merck & Co.   Second‐line or more         Phase 2       Open‐label     62           15‐89       327          Melanoma                                        Median 10                     Pembrolizumab 2 mg/kg every 3 weeks                                                                    Pembrolizumab 10 mg/kg every 3 weeks                                    Chemotherapy control
  KEYNOTE‐006                 2015;2017    Merck Sharp & Dohme, a subsidiary of Merck & Co.   First‐line or second‐line   Phase 3       Open‐label     62           18‐89       497          Melanoma                                        Median 7.9                    Pembrolizumab 10 mg/kg every 2 weeks                                                                   Pembrolizumab 10 mg/kg every 3 weeks                                    Ipilimumab 3 mg/kg every 3 weeks
  KEYNOTE‐010                 2016         Merck & Co.                                        Second‐line or more         Phase 2/3     Open‐label     63           56‐69       634          Non--small‐cell lung cancer                     Median 13.1                   Pembrolizumab 2 mg/kg every 3 weeks                                                                    Pembrolizumab 10 mg/kg every 3 weeks                                    Chemotherapy control
  KEYNOTE‐021                 2016         Merck & Co.                                        First‐line                  Phase 3       Open‐label     63           54‐70       48           Non--small‐cell lung cancer                     Median 10.6                   Pembrolizumab 200 mg every 3 weeks plus chemotherapy                                                   NA                                                                      Chemotherapy control
  KEYNOTE‐024                 2016         Merck & Co.                                        First‐line                  Phase 3       Open‐label     65           33‐90       187          Non--small‐cell lung cancer                     Median 11.2                   Pembrolizumab 200 mg every 3 weeks                                                                     NA                                                                      Chemotherapy control
  KEYNOTE‐045                 2017         Merck & Co.                                        Second‐line                 Phase 3       Open‐label     66           26‐88       402          Urothelial carcinoma                            Median 14.1                   Pembrolizumab 200 mg every 3 weeks                                                                     NA                                                                      Chemotherapy control
  KEYNOTE‐054                 2018         Merck & Co.                                        Second‐line or more         Phase 3       Double‐blind   54           19‐88       628          Melanoma                                        Median 15                     Pembrolizumab 200 mg every 3 weeks                                                                     NA                                                                      Placebo
  KEYNOTE‐061                 2018         Merck Sharp & Dohme, a subsidiary of Merck & Co.   First‐line                  Phase 3       Open‐label     61           53‐70       410          Gastric or gastro‐oesophageal junction cancer   Median 7.9                    Pembrolizumab 200 mg every 3 weeks                                                                     NA                                                                      Chemotherapy control
  KEYNOTE‐189                 2018         Merck & Co.                                        First‐line                  Phase 3       Double‐blind   64           34‐84       363          Non--small‐cell lung cancer                     Median 10.5                   Pembrolizumab 200 mg every 3 weeks plus chemotherapy                                                   NA                                                                      Chemotherapy control
  OAK                         2017         F. Hoffmann‐La Roche Ltd, Genentech, Inc.          Second‐line or more         Phase 3       Open‐label     63           33‐85       747          Non--small‐cell lung cancer                     Minimum 19                    Atezolizumab 1200 mg every 3 weeks                                                                     NA                                                                      Chemotherapy control
  ONO‐4538‐12, ATTRACTION‐2   2017         Ono Pharmaceutical and Bristol‐Myers Squibb        Second‐line or more         Phase 3       Double‐blind   62           53‐69       348          Gastric or gastro‐oesophageal junction cancer   Median 12                     Nivolumab 3 mg/kg every 2 weeks                                                                        NA                                                                      Placebo
  PACIFIC study               2017         AstraZeneca                                        Second‐line or more         Phase 3       Double‐blind   64           23‐90       500          Non--small‐cell lung cancer                     Median 14.5                   Durvalumab 10 mg/kg every 2 weeks                                                                      NA                                                                      Placebo
  POPLAR Study                2016         F. Hoffmann‐La Roche Ltd, Genentech, Inc.          Second‐line or more         Phase 2       Open‐label     62           36‐84       169          Non--small‐cell lung cancer                     Median 13                     Atezolizumab 1200 mg every 3 weeks                                                                     NA                                                                      Chemotherapy control

NA, not available.

John Wiley & Sons, Ltd

###### 

Number of patients with immune‐related pneumonitis (data for main analysis)

  Trial name                  Types of treatment                Number of patients for adverse events   Pneumonitis events (Grade 1‐5)   Pneumonitis events (Grade 3 ‐5)   Data source                                        
  --------------------------- --------------------------------- --------------------------------------- -------------------------------- --------------------------------- ------------- ----- ----- ---- ---- ---- ---- ---- --------------------
  CheckMate 017               Nivolumab                         NA                                      Chemotherapy                     131                               NA            129   2     NA   0    2    NA   0    ClinicalTrials.gov
  CheckMate 025               Nivolumab                         NA                                      Everolimus                       406                               NA            397   25    NA   67   8    NA   12   ClinicalTrials.gov
  CheckMate 026               Nivolumab                         NA                                      Chemotherapy                     267                               NA            263   7     NA   0    7    NA   0    ClinicalTrials.gov
  CheckMate 037               Nivolumab                         NA                                      Chemotherapy                     268                               NA            102   1     NA   0    1    NA   0    ClinicalTrials.gov
  CheckMate 057               Nivolumab                         NA                                      Chemotherapy                     287                               NA            268   4     NA   0    4    NA   0    ClinicalTrials.gov
  CheckMate 066               Nivolumab                         NA                                      Chemotherapy                     206                               NA            205   2     NA   0    2    NA   0    ClinicalTrials.gov
  CheckMate 067               Nivolumab                         Nivolumab plus ipilimumab               Ipilimumab                       313                               313           311   2     6    2    2    6    2    ClinicalTrials.gov
  CheckMate 069               Nivolumab plus ipilimumab         NA                                      Ipilimumab                       94                                NA            46    5     NA   0    5    NA   0    ClinicalTrials.gov
  CheckMate 141               Nivolumab                         NA                                      Standard therapy                 236                               NA            111   2     NA   0    2    NA   0    ClinicalTrials.gov
  CheckMate 214               Nivolumab plus ipilimumab         NA                                      Sunitinib                        547                               NA            535   1     NA   0    1    NA   0    Published article
  CheckMate 227               Nivolumab plus ipilimumab         Nivolumab                               Chemotherapy                     576                               391           570   22    9    3    13   6    2    Published article
  CheckMate 238               Nivolumab                         NA                                      Ipilimumab                       452                               NA            453   6     NA   11   0    NA   4    Published article
  KEYNOTE‐002                 Pembrolizumab                     Pembrolizumab                           Chemotherapy                     178                               179           171   1     3    0    1    3    0    ClinicalTrials.gov
  KEYNOTE‐006                 Pembrolizumab                     Pembrolizumab                           Ipilimumab                       278                               277           256   2     2    4    2    2    4    ClinicalTrials.gov
  KEYNOTE‐010                 Pembrolizumab                     Pembrolizumab                           Chemotherapy                     339                               343           309   8     9    2    8    9    2    ClinicalTrials.gov
  KEYNOTE‐021                 Pembrolizumab plus chemotherapy   NA                                      Chemotherapy                     59                                NA            62    4     NA   0    1    NA   0    ClinicalTrials.gov
  KEYNOTE‐024                 Pembrolizumab                     NA                                      Chemotherapy                     154                               NA            150   7     NA   1    7    NA   1    ClinicalTrials.gov
  KEYNOTE‐045                 Pembrolizumab                     NA                                      Chemotherapy                     266                               NA            255   6     NA   0    6    NA   0    ClinicalTrials.gov
  KEYNOTE‐054                 Pembrolizumab                     NA                                      Placebo                          509                               NA            502   17    NA   3    4    NA   0    Published article
  KEYNOTE‐061                 Pembrolizumab                     NA                                      Chemotherapy                     294                               NA            276   8     NA   0    2    NA   0    Published article
  KEYNOTE‐189                 Pembrolizumab plus chemotherapy   NA                                      Chemotherapy                     405                               NA            202   18    NA   5    11   NA   4    Published article
  OAK                         Atezolizumab                      NA                                      Chemotherapy                     609                               NA            578   5     NA   1    5    NA   1    ClinicalTrials.gov
  ONO‐4538‐12, ATTRACTION‐2   Nivolumab                         NA                                      Placebo                          330                               NA            161   1     NA   0    1    NA   0    Published article
  PACIFIC study               Durvalumab                        NA                                      Placebo                          475                               NA            234   161   NA   58   16   NA   6    Published article
  POPLAR Study                Atezolizumab                      NA                                      Chemotherapy                     142                               NA            135   1     NA   0    1    NA   0    ClinicalTrials.gov

NA, not available.

John Wiley & Sons, Ltd

3.2. All‐grade (grade 1‐5) pneumonitis {#cam42104-sec-0015}
--------------------------------------

The ORs for pairwise comparisons of all‐grade pneumonitis are shown in [Table S4](#cam42104-sup-0002){ref-type="supplementary-material"}. Compared with chemotherapy, nivolumab, pembrolizumab, nivolumab plus ipilimumab therapy were associated with a statistically significant higher risk of all‐grade pneumonitis (nivolumab vs chemotherapy: OR = 5.49, 95% CI: 2.15‐13.98; pembrolizumab vs chemotherapy: OR = 5.40, 95% CI: 2.39‐12.17; nivolumab plus ipilimumab therapy vs chemotherapy: OR = 7.51, 95% CI: 2.23‐25.22), with moderate quality of evidence respectively.

Results of NMA for all‐grade pneumonitis risk were displayed in Figure [3](#cam42104-fig-0003){ref-type="fig"}A and [Figure S1](#cam42104-sup-0002){ref-type="supplementary-material"}. Compared with chemotherapy, nivolumab and pembrolizumab were associated with an increased risk of all‐grade pneumonitis (nivolumab vs chemotherapy: OR = 6.29, 95% CrI: 2.67‐16.75; pembrolizumab vs chemotherapy: OR = 5.78, 95% CrI: 2.79‐13.24), with moderate quality of evidence respectively. Compared with chemotherapy, nivolumab plus ipilimumab therapy was associated with an increased risk of all‐grade pneumonitis (OR = 14.82, 95% CrI: 5.48‐47.97), with low quality of evidence. Compared with nivolumab, nivolumab plus ipilimumab therapy was also associated with an increased risk of all‐grade pneumonitis (OR = 2.34, 95% CrI: 1.07‐5.77), with high quality of evidence. Compared with nivolumab plus ipilimumab therapy, pembrolizumab plus chemotherapy was associated with a decreased risk of all‐grade pneumonitis (OR = 0.18, 95% CrI: 0.04‐0.89), with moderate quality of evidence.

![Bayesian network meta‐analysis of pneumonitis. Comparisons should be read from left to right. The column treatment is compared with the row treatment. Bold underline cells are significant. Results represent pooled odds ratios and 95% credible intervals for pneumonitis of Grade 1‐5 (A) and Grade 3‐5 (B). Odds ratio \> 1 favors row‐defining treatment](CAM4-8-2664-g003){#cam42104-fig-0003}

3.3. High‐grade (grade 3‐5) pneumonitis {#cam42104-sec-0016}
---------------------------------------

The ORs for pairwise comparisons of high‐grade pneumonitis are shown in [Table S5](#cam42104-sup-0002){ref-type="supplementary-material"}. Compared with chemotherapy, nivolumab, pembrolizumab, nivolumab plus ipilimumab therapy were associated with a statistically significant higher risk of high‐grade pneumonitis (nivolumab vs chemotherapy: OR = 5.04, 95% CI: 1.80‐14.15; pembrolizumab vs chemotherapy: OR = 4.88, 95% CI: 2.16‐11.05; nivolumab plus ipilimumab therapy vs chemotherapy: OR = 6.56, 95% CI: 1.47‐29.19), with moderate quality of evidence respectively.

Results of NMA for high‐grade pneumonitis risk were displayed in Figure [3](#cam42104-fig-0003){ref-type="fig"}B and [Figure S2](#cam42104-sup-0002){ref-type="supplementary-material"}. Compared with chemotherapy, nivolumab and pembrolizumab were associated with an increased risk of high‐grade pneumonitis (nivolumab vs chemotherapy: OR = 5.95, 95% CrI: 2.35‐17.29; pembrolizumab vs chemotherapy: OR = 5.33, 95% CrI: 2.49‐12.97), with moderate quality of evidence respectively. Nivolumab plus ipilimumab therapy was associated with an increased risk of high‐grade pneumonitis (OR = 15.26, 95% CrI: 5.05‐55.52), with low quality of evidence. Compared with nivolumab, nivolumab plus ipilimumab therapy was associated with an increased risk of high‐grade pneumonitis (OR = 2.54, 95% CrI: 1.02‐7.31), with high quality of evidence. Compared with nivolumab plus ipilimumab therapy, pembrolizumab plus chemotherapy was associated with a decreased risk of high‐grade pneumonitis (OR = 0.11, 95% CrI: 0.02‐0.66), with moderate quality of evidence.

3.4. Ranks and meta‐regression analyses {#cam42104-sec-0017}
---------------------------------------

The ranks of all treatments were presented in [Table S6](#cam42104-sup-0002){ref-type="supplementary-material"}. Nivolumab plus ipilimumab therapy had the highest risk of both all‐grade and high‐grade pneumonitis among PD1/PD‐L1 inhibitor‐related therapeutic regimens. Meta‐regression analyses did not reveal any prespecified factors that influenced the estimated effects significantly ([Table S7](#cam42104-sup-0002){ref-type="supplementary-material"}).

3.5. Model fit and inconsistence check {#cam42104-sec-0018}
--------------------------------------

The model fit was evaluated using the posterior mean of the residual deviance, which was 42 and 38 for all‐grade and high‐grade pneumonitis, respectively. The model\'s overall fit was relatively satisfactory. According to the forest plots, the statistically inconsistency between direct and indirect comparisons was low for all‐grade and high‐grade pneumonitis outcomes. All loops were consistent ([Figure S3](#cam42104-sup-0002){ref-type="supplementary-material"}).

3.6. Reporting bias and sensitivity analysis {#cam42104-sec-0019}
--------------------------------------------

[Figure S4](#cam42104-sup-0002){ref-type="supplementary-material"} present the adjusted funnel plot for the pneumonitis network. The funnel plots of all‐grade and high‐grade pneumonitis outcomes did not show asymmetry, suggesting no potential risk of reporting bias. Sensitivity analyses based on published data did not indicate any major influence on the outcomes ([Figure S5‐S7](#cam42104-sup-0002){ref-type="supplementary-material"}).

4. DISCUSSION {#cam42104-sec-0020}
=============

4.1. Summary of key findings {#cam42104-sec-0021}
----------------------------

This study has 3 key findings: First, there was moderate quality of evidence that nivolumab, pembrolizumab and nivolumab plus ipilimumab therapy increased the risk of all‐grade and high‐grade immune‐related pneumonitis, compared with chemotherapy. Second, nivolumab plus ipilimumab therapy was associated with an increased risk of all‐grade pneumonitis compared with nivolumab, with high quality of evidence. Third, nivolumab plus ipilimumab therapy had the highest risk of both all‐grade and high‐grade pneumonitis among different types of PD1/PD‐L1 inhibitor‐related therapeutic regimens.

4.2. Comparison with other studies {#cam42104-sec-0022}
----------------------------------

Previous published systematic reviews and meta‐analyses regarding the immune‐related risk of pneumonitis have shown that PD1 inhibitors are associated with an increased risk of immune‐related pneumonitis compared with chemotherapy.[8](#cam42104-bib-0008){ref-type="ref"}, [15](#cam42104-bib-0015){ref-type="ref"}, [24](#cam42104-bib-0024){ref-type="ref"} The Bayesian network meta‐analysis in our study allows us to compare the therapeutic regimens indirectly when no head‐to‐head trial existed. There was high to moderate quality evidence showing that nivolumab plus ipilimumab therapy was associated with an increased risk of pneumonitis, compared with chemotherapy and nivolumab respectively.

Two studies have previously investigated the differences in the toxicities of PD1 and PD‐L1 inhibitors.[24](#cam42104-bib-0024){ref-type="ref"}, [25](#cam42104-bib-0025){ref-type="ref"} Khunger et al reported a higher incidence of immune‐related pneumonitis with use of PD‐1 inhibitors compared with PD‐L1 inhibitors in patients with nonsmall cell lung cancer.[24](#cam42104-bib-0024){ref-type="ref"} The summary of incidence of all‐grade and high‐grade pneumonitis was also reported in [Table S8](#cam42104-sup-0002){ref-type="supplementary-material"} of our study. Pillai et al found a slight increase in pneumonitis risk with PD‐1 inhibitors.[25](#cam42104-bib-0025){ref-type="ref"} It should be noted that no RCT to date has directly compared the risk of immune‐related pneumonitis between PD‐1 and PD‐L1 inhibitors. We still lack direct evidence to make such conclusion. In our study, indirect comparison showed an increased but not statistically significant risk of immune‐related pneumonitis with use of nivolumab or pembrolizumab compared with durvalumab or atezolizumab, respectively.

4.3. Strength and limitations of study {#cam42104-sec-0023}
--------------------------------------

To our knowledge, this is the first systematic review and NMA which provides the most current and structured evidence of immune‐related pneumonitis for PD1/PD‐L1 inhibitor‐related therapeutic regimens. Studies from ClinicalTrials.gov were searched carefully. Both published and unpublished data were extracted. We believe that all relevant RCTs were included in analyses and the publication bias was reduced as much as possible. The main limitation of this study is that indirect comparisons from NMA are very likely to suffer bias through confounding by study‐level characteristics. The results from indirect comparisons should be interpreted with caution as direct evidence is lacking. However, the trial populations and study characteristics were very comparable to the target population of this NMA. We further evaluated the potential confounding factors with meta‐regression analyses, which showed no major influence to our primary results. Secondly, compared with chemotherapy, we did not find significant increase in pneumonitis risk for atezolizumab or durvalumab. It did not indicate that there was no risk of pneumonitis with the use of these 2 agents. Compared with chemotherapy, the direction of risks for durvalumab and atezolizumab were both positive (more than one), despite of lacking significance. One of the potential reasons of lacking significance may due to limited number of trials with positive results for these 2 agents. More RCTs are needed in the future to detect their potential risks further.

4.4. Research and clinical implications {#cam42104-sec-0024}
---------------------------------------

Traditionally, most assessments of safety of PD1/PD‐L1 inhibitors come from comparisons with chemotherapy. Despite our current systematic review and NMA provides insight in these comparisons from indirect comparisons, evidence on head‐to‐head comparisons among different PD1/PD‐L1 inhibitor‐related therapeutic regimens is still lacking. New trials comparing between different PD1/PD‐L1 inhibitor‐related therapeutic regimens are needed. Future trials could also be conducted to assess the safety of the combination of PD1/PD‐L1 inhibitor and chemotherapy to enrich the evidence.

Two clinical implications should be noted. First, nivolumab plus ipilimumab therapy had the highest pneumonitis risk among different PD1/PD‐L1 inhibitor‐related therapeutic regimens. The results of both all‐grade and high‐grade pneumonitis outcomes were stable in sensitivity analysis. It should be noted that ipilimumab blocks cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) as well as augments T‐cell immune response as an immunomodulator. CTLA‐4 has both cell intrinsic activities and cell extrinsic activities. In contrast, immunoregulation by PD‐1 is antigen specific and cell intrinsic.[26](#cam42104-bib-0026){ref-type="ref"} Consistent with their mechanism of action, immune‐related adverse event rates are more likely to be higher for the combination use of PD1 and CTLA4 inhibitors, compared with using PD1 inhibitors alone. Moreover, immune‐related all‐grade and high‐grade pneumonitis were also significant for both nivolumab and pembrolizumab therapy. Physicians may need to consider the increased pneumonitis risk when choosing these therapies for cancer patients. Second, the combination of chemotherapy and PD1/PD‐L1 inhibitor had a decreased risk of immune‐related pneumonitis, compared with using nivolumab plus ipilimumab. These results may be taken into account by the physicians in decision making when choosing among the different combinations of therapies.

5. CONCLUSIONS {#cam42104-sec-0025}
==============

This systematic review and network meta‐analysis offers substantial evidence and demonstrates that PD‐1 inhibitor is very likely to result in a higher risk of immune‐related pneumonitis compared with chemotherapy. Nivolumab plus ipilimumab therapy had the highest pneumonitis risk. These findings may be taken into account by the physicians in decision making when choosing among different PD1/PD‐L1 inhibitor‐related therapeutic regimens for cancer patients.
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